Atara Biotherapeutics Inc
ATRA
查看详细走势图
4.880USD
+0.370+8.20%
收盘 02/06, 16:00（美东）报价延迟15分钟
35.18M总市值
1.69市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+8.20%
5天
-6.15%
1月
-67.34%
6月
-55.47%
今年开始到现在
-73.02%
1年
-51.49%
查看详细走势图
TradingKey Atara Biotherapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Atara Biotherapeutics Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名144/392位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价9.33。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Atara Biotherapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Atara Biotherapeutics Inc亮点
亮点风险
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
业绩高增长
公司营业收入稳步增长，连续3年增长102.82%
估值高估
公司最新PE估值1.69，处于3年历史高位
机构加仓
最新机构持股3.30M股，环比增加0.09%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值18.94K
分析师目标
根据
4
位分析师
持有
评级
9.333
目标均价
+92.04%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Atara Biotherapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Atara Biotherapeutics Inc简介
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
公司代码ATRA
公司Atara Biotherapeutics Inc
CEONguyen (Anhco)
网址https://www.atarabio.com/
相关品种
